Flat-Rate Subscription to La Merie Reports with 24/7 Online Access
Subscription to this product provides online access during one year to all reports published by La Merie and available in the online store during the subscription. Among La Merie reports are more than 100 Competitor Analysis reports as well as a growing number of Brief and Full Reports. La Merie reports are continuously updated and newly released. Reports can be searched for and identified in La Merie’s online store. Instant access is gained via the Subscriber Access placed on each report description using E-mail Address and Password of Registered Users. After purchase of the product, access will be activated within 24 hours and an e-mail sent to ensure customer support.
Features of the Flat-Rate Online Access to La Merie Reports:- 24/7 access to all La Merie reports
- Instant online download of report in pdf format
- Dynamic content (more than 50 updates and new releases per year)
- E-mail notification of new releases and updates
- Broad coverage of Oncology, Biosimilars and Biologics
- Great savings over individual purchases
Reports of the Competitor Analysis Series deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases and technologies provided in a tabular format and fully referenced. Each project described in the Competitor Analysis reports is specified for its Target or Mechanism of Action, Product Category, Indication,R&D Phase and Comment with a hyperlink leading to the source of information.
Brief Reports include description of the target background and scientific rational, drug discovery approaches, preclinical and clinical experience, status of development, extensive individual project profiles, competitor analysis and status of development and assessment.
Examples of Oncology related Competitor Analysis- Antibody-Drug Conjugates (ADC)
- Aurora Kinase Inhibitors
- Bcr-Abl and Src Kinase Inhibitors
- c-MET/HGF Inhibitors
- CD3 Antagonists
- CD19 Antagonists
- CD20 Antibodies
- CD22 Antibodies
- CD30 Antibodies
- CD40/L
- CEA Antibodies
- CHK and KSP/Eg5 Inhibitors
- CXCR and CXCL Agonists & Antagonists
- EGF-R Agonists and Antagonists
- EpCAM Antagonists
- HDAC Inhibitors
- Heat shock protein 90 (Hsp90) Inhibitors
- Hypoxia-Inducible Factor (HIF)
- IGF-1R Antagonists
- Immunocytokines
- Immunotoxins
- Integrin Antagonists
- Janus Kinase (JAK) Inhibitors
- MEK Inhibitors
- Novel Mitotic Kinase Inhibitors
- PARP Inhibitors
- PDGF-R Agonists and Antagonists
- PI3K-AKT-mTOR Inhibitors
- Polo-like Kinase 1 (Plk-1) Inhibitors
- Proteasome Inhibitors
- Ras-Raf-MEK-ERK Inhibitors
- Selective Estrogen Receptor Modulators (SERM)
- TGF-R Agonists and Antagonists
- VEGF and VEGF-R Agonists and Antagonists
- Erythropoiesis Stimulating Agents (ESA)
- G-CSF and GM-CSF
- Interferon
- Thrombopoiesis Stimulating Agent
- Insulin
- Human Growth Hormone
- Thrombolytic Agents
- Interleukin-17 (IL-17) and IL-17 Receptor Antagonists
- Coagulation Factors 2009: Target Pipeline and Corporate Benchmark Analysis
- CD40 and CD40L (CD154) Agonists and Antagonists
- Interleukin-12 (IL-12) and IL-23 Antagonists
- Interleukin-13 (IL-13) Antibodies
- Syk Kinase Inhibitors
- BM-CSF antibodies
- Death Receptors TRAIL-R1/2
- Brief Report HDL Raising Therapies
- Brief Report PKSK9
- Brief Report Interleukin Receptor Agonists
- Brief Report GLP-1 Analogs
- Brief Report Insulin
- Biosimilar Series Updates
- Vaccine Series New Releases
- Anti-Infective Antibodies
- TLR Agonists and Antagonists
